(Reuters) -Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million. The company's shares opened at $16.12 apiece, ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

Sionna Therapeutics (SION), which is developing drugs to treat cystic fibrosis, has filed to raise $100M through an initial public offering. While Sionna (SION) didn't disclose terms in its SEC filing ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Sionna Therapeutics and Odyssey Therapeutics join Metsera and Maze in filing for IPOs, with Sionna focused on cystic fibrosis ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

New Canaan 5, West Haven/Sacred Heart 0 West Haven/Sacred Heart 0-0-0 0 New Canaan 3-2-0 5 NC: Serena O’Connor 3g, Maddie ...